Today, Zymeworks announced that it is investigating zanidatamab, a bispecific antibody therapy targeting HER2, and has achieved positive results in a first-line clinical trial for the treatment of HER2-expressing gastroesophageal adenocarcinoma (GEA) patients
As of March 18, 2021, of the 22 patients that can be evaluated, zanidatamab was used in combination with standard chemotherapy to achieve a confirmed objective response rate of 68.
The latest results of this experiment will be announced at the ESMO conference on September 16
Zanidatamab is a bispecific antibody that can simultaneously bind to two non-overlapping epitopes of HER2
This unique design produces multiple mechanisms of action, including dual HER2 signal blockade, increased clearance of HER2 protein from the cell surface, and enhanced antibody-mediated cytotoxicity, resulting in encouraging anti-tumor activity in patients
BeiGene has reached a research and development cooperation agreement with Zymeworks, and has obtained the exclusive authorization for the development and promotion of zanidatamab in Asia (except Japan), Australia and New Zealand
The application for clinical trials of this innovative treatment in China has also passed "implicit permission
▲Zanidatamab has a unique mechanism of action (picture source: reference )
 Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress.
Retrieved September 12, 2021, from https:// news/home/20210912005060/en
 Zymeworks Corporate Presentation.
Retrieved December 5, 2020, from https://s23.
(The original text has been deleted)